echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Jyseleca (filgotinib) treatment for rheumatoid arthritis: approved by Japan and the European Union.

    Jyseleca (filgotinib) treatment for rheumatoid arthritis: approved by Japan and the European Union.

    • Last Update: 2020-10-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Rheumatic arthritis (rheumatic arthritis, RA) is a common type of acute or chronic connective tissue inflammation.
    it usually causes joint fever, swelling and pain.
    most common are wrists and hands that involve the same joints on both sides of the body.
    the disease may also affect other parts of the body.
    this can lead to low red blood cells, inflammation of the lungs, and inflammation of the heart.
    may also have fever and lack of vitality.
    usually symptoms are gradually more than a few weeks to months.
    Gilead Sciences announced Friday that the European Commission has approved Jyseleca (filgotinib) to treat adult patients with moderate to severe active rheumatoid arthritis (RA) who do not respond adequately to one or more treatments.
    said earlier in the day that Japanese regulators had approved Jyseleca's treatment of RA patients who did not respond well to conventional therapies.
    Jyseleca (filgotinib) is an oral JAK1 inhibitor that Gilead is developing once a day.
    both approvals are based on the latest results from phase III FINCH and Phase II DARWIN studies, which showed improved clinical symptoms and signs in patients receiving Jyseleca (filgotinib) and reduced disease activity.
    in Japan, Gilead will be in charge of Jyseleca's supply, while Eisai will be responsible for product distribution.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.